within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B05A_BloodAndRelatedProducts.B05AA09_HemoglobinRaffimer;

model HemoglobinRaffimer
  extends Pharmacolibrary.Drugs.ATC.B.B05AA09;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>B05AA09</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Hemoglobin raffimer (also known as Hemolink, MP4, or oxygen therapeutic) is a modified hemoglobin-based oxygen carrier developed to temporarily substitute blood transfusions by providing an alternative for oxygen delivery in situations such as hypovolemia or trauma. It is not currently approved or marketed for clinical use as development was discontinued.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data available in humans or animals for model parameters. The following model estimates are provided based on common properties of high-molecular-weight hemoglobin-based oxygen carriers administered intravenously.</p><h4>References</h4><ol><li><p>Spahn, DR, &amp; Kocian, R (2005). Artificial O2 carriers: status in 2005. <i>Current pharmaceutical design</i> 11(31) 4099–4114. DOI:<a href=\"https://doi.org/10.2174/138161205774913354\">10.2174/138161205774913354</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16378514/\">https://pubmed.ncbi.nlm.nih.gov/16378514</a></p></li><li><p>Carmichael, FJ, et al., &amp; Greenburg, AG (2000). A phase I study of oxidized raffinose cross-linked human hemoglobin. <i>Critical care medicine</i> 28(7) 2283–2292. DOI:<a href=\"https://doi.org/10.1097/00003246-200007000-00017\">10.1097/00003246-200007000-00017</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10921554/\">https://pubmed.ncbi.nlm.nih.gov/10921554</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end HemoglobinRaffimer;
